Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAC-1 in Advanced Malignancies (Component 1)
NCT02355535Phase 1Completed
- Sponsor
- Vanquish Oncology
- Start
- Feb 2015
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PAC-1 in Neuroendocrine Neoplasm (NEN), solid tumor and lymphoma, sponsored by Vanquish Oncology. Primary endpoint: Maximum Tolerated Dose. Started Feb 2015; status: completed.
02
Drugs
PAC-1
03
Conditions
Neuroendocrine Neoplasm (NEN)solid tumorlymphoma
Beyond the preview
Go deeper on NCT02355535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02355535.